$SHCR At $10 a share this company took advantage of crazy valuations SPACS are willing to pay for decent companies. Insiders sold a bunch of stock on the merger at a price North of $3.8 Billion ($10 a share). The shorts and other investors used the public liquidity to sell the stock down to $6.45 or close to a $2.7 Billion valuation less cash on balance sheet of $400. $2.3 Billion for $31 Million in 2021 EBITDA Still crazy expensive. The good news is that the company should grow EBITDA quickly to $100 and the stock can grow into its valuation. Probably a good place to start accumulating some stock if you have a long term perspective.
@JeffArnoldsGlasses @johns45, I have no idea where John is getting his PT. These companies get valued on EV/rev usually, not EBITDA or PE. Healthcare tech and disruption stocks typically get a ‘21 EV/rev of 10-15 easily (e.g. $TDOC $GDRX $PHR, and etc.), for this type of revenue growth. Their current ‘21 EV/rev is ~5 right now…it is just an added bonus that they are EBITDA positive, as most are not. If you believe their ‘22 projections, they are even more behind in peer multiples.